Bottom line
RXL vs RYHIX: the short answer
RXL (ProShares Ultra Health Care) and RYHIX (Health Care Fund) are both etfs.
RXL is cheaper at 0.95% vs 1.38% — a difference of $43 a year per $10,000 invested.
Over five years, RXL returned +7.2% a year vs +5.1% for RYHIX.
Updated Nov 19, 2026
RXL vs RYHIX side by side
| RXL | RYHIX | |
|---|---|---|
| Type | ETF | Mutual fund |
| Fund family | ProShares | Guggenheim |
| Category | Health Care Sector | Health Care Sector |
| Expense ratio | 0.95% | 1.38% |
| Annual cost per $10k | $95 | $138 |
| 10-yr cost on $10k (prospectus) | $1,305 | $1,709 |
| Max front load | None | — |
| 12b-1 fee | — | 0% |
| 1-yr return | +19.7% | +14.4% |
| 5-yr return (annualized) | +7.2% | +5.1% |
| 10-yr return (annualized) | +12.6% | +7.9% |
| Best quarter | +29.7% | +18.7% |
| Worst quarter | −28.9% | −14.4% |
| Net assets (fund) | $72.1M | $19.4M |
| Number of holdings | 70 | 135 |
| Portfolio turnover | 4% | 244% |
| Returns as of | Dec 31, 2025 | Dec 31, 2025 |
Source: SEC Form N-PORT and fund prospectuses
Year-by-year returns
| Year | RXL | RYHIX | Difference |
|---|---|---|---|
| 2025 | +19.7% | +14.4% | +5.2% |
| 2024 | −2.7% | +0.6% | −3.3% |
| 2023 | −3.2% | +5.8% | −9.0% |
| 2022 | −15.1% | −11.6% | −3.5% |
| 2021 | +47.8% | +19.2% | +28.6% |
| 2020 | +19.2% | +18.9% | +0.3% |
| 2019 | +38.9% | +22.8% | +16.1% |
| 2018 | +5.4% | +1.6% | +3.8% |
| 2017 | +46.0% | +23.5% | +22.5% |
| 2016 | −8.9% | −9.4% | +0.4% |
Source: Fund prospectus bar charts
Holdings overlap
20 of RXL's top 25 holdings also appear in RYHIX's top 25.
| Holding | RXL | RYHIX |
|---|---|---|
| Eli Lilly & Co. | 12.67% | 3.63% |
| Johnson & Johnson | 7.86% | 2.88% |
| AbbVie, Inc. | 5.57% | 2.52% |
| UnitedHealth Group, Inc. | 4.98% | 2.22% |
| Merck & Co., Inc. | 4.26% | 2.04% |
| Thermo Fisher Scientific, Inc. | 2.68% | 1.61% |
| Amgen, Inc. | 2.62% | 1.56% |
| Gilead Sciences, Inc. | 2.41% | 1.39% |
| Intuitive Surgical, Inc. | 2.18% | 1.31% |
| Pfizer, Inc. | 2.15% | 1.25% |
| Abbott Laboratories | 2.15% | 1.42% |
| Bristol-Myers Squibb Co. | 1.68% | 1.22% |
| CVS Health Corp. | 1.67% | 1.31% |
| Danaher Corp. | 1.66% | 1.30% |
| Vertex Pharmaceuticals, Inc. | 1.64% | 1.34% |
Source: SEC Form N-PORT
RXL top 10
- Eli Lilly & Co. — 12.67%
- ProShares GENIUS Money Market ETF — 11.81%
- Johnson & Johnson — 7.86%
- AbbVie, Inc. — 5.57%
- UnitedHealth Group, Inc. — 4.98%
- Merck & Co., Inc. — 4.26%
- Repurchase Agreement — 2.91%
- Thermo Fisher Scientific, Inc. — 2.68%
- Amgen, Inc. — 2.62%
- Gilead Sciences, Inc. — 2.41%
RYHIX top 10
- Eli Lilly & Company — 3.63%
- Johnson & Johnson — 2.88%
- Abbvie Inc — 2.52%
- Unitedhealth Group Inc — 2.22%
- Merck & Company Inc — 2.04%
- Thermo Fisher Scientific Inc — 1.61%
- Amgen Inc — 1.56%
- Abbott Laboratories — 1.42%
- Gilead Sciences Inc — 1.39%
- Vertex Pharmaceuticals Inc — 1.34%
FAQ
What is the difference between RXL and RYHIX?
RXL (ProShares Ultra Health Care) and RYHIX (Health Care Fund) are both etfs. RXL is cheaper at 0.95% vs 1.38% — a difference of $43 a year per $10,000 invested.
Which is cheaper, RXL or RYHIX?
RXL has the lower expense ratio (0.95%).
Should I own both RXL and RYHIX?
Because their portfolios differ, owning both can add diversification — check how they fit your overall allocation.
Educational comparison based on public filings; not investment advice. Past performance does not guarantee future results.